JP2020502224A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502224A5
JP2020502224A5 JP2019533666A JP2019533666A JP2020502224A5 JP 2020502224 A5 JP2020502224 A5 JP 2020502224A5 JP 2019533666 A JP2019533666 A JP 2019533666A JP 2019533666 A JP2019533666 A JP 2019533666A JP 2020502224 A5 JP2020502224 A5 JP 2020502224A5
Authority
JP
Japan
Prior art keywords
crystal
crystalline form
purity
composition according
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2017/045731 external-priority patent/WO2018117153A1/en
Publication of JP2020502224A publication Critical patent/JP2020502224A/ja
Publication of JP2020502224A5 publication Critical patent/JP2020502224A5/ja
Priority to JP2022207814A priority Critical patent/JP2023024729A/ja
Priority to JP2024134769A priority patent/JP2024161449A/ja
Pending legal-status Critical Current

Links

JP2019533666A 2016-12-21 2017-12-20 ヤヌスキナーゼ阻害剤の結晶形 Pending JP2020502224A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022207814A JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437,262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207814A Division JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形

Publications (2)

Publication Number Publication Date
JP2020502224A JP2020502224A (ja) 2020-01-23
JP2020502224A5 true JP2020502224A5 (enExample) 2021-02-04

Family

ID=60991475

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533666A Pending JP2020502224A (ja) 2016-12-21 2017-12-20 ヤヌスキナーゼ阻害剤の結晶形
JP2022207814A Pending JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A Pending JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022207814A Pending JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A Pending JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Country Status (13)

Country Link
US (1) US11339181B2 (enExample)
EP (1) EP3559003B1 (enExample)
JP (3) JP2020502224A (enExample)
KR (1) KR102788829B1 (enExample)
CN (2) CN110325536A (enExample)
AU (1) AU2017380213B2 (enExample)
BR (1) BR112019012210A2 (enExample)
CA (1) CA3044771A1 (enExample)
ES (1) ES2926986T3 (enExample)
IL (1) IL267393B2 (enExample)
MX (1) MX386181B (enExample)
TW (1) TWI822666B (enExample)
WO (1) WO2018117153A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich
JP7597714B2 (ja) * 2019-08-07 2024-12-10 ロート製薬株式会社 涙液分泌促進用眼科組成物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
JP7807247B2 (ja) * 2021-02-05 2026-01-27 ロート製薬株式会社 シェーグレン症候群治療剤
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
AU2024229918A1 (en) * 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500666A (ja) * 2005-07-07 2009-01-08 トムソン ライセンシング 対応スタンドを備えたフラット画面ディスプレイシステム
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
BRPI1012108B8 (pt) * 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
BR112017026173A2 (pt) * 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo

Similar Documents

Publication Publication Date Title
CA2903288C (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
CA2800541C (en) Soluble guanylate cyclase activators
JP2015512942A5 (enExample)
JP2016528179A (ja) 製造方法及びmdm2阻害剤の結晶形
CL2008002184A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension pulmonar, osteoporosis, artritis, entre otras.
JP6592512B2 (ja) 三環式アトロプ異性体の化合物
JP2020525512A (ja) 癌および他の疾患を処置するためのATF4阻害剤としての2−(4−クロロフェノキシ)−N−((1−(2−(4−クロロフェノキシ)エチンアゼチジン(ethynazetidin)−3−イル)メチル)アセトアミド誘導体および関連化合物
JP2011523412A5 (enExample)
TW201209026A (en) Process for the preparation of pleuromutilins
ME02612B (me) Tenofovir alafenamid hemifumarat
CA2776342C (en) Agomelatine and pharmaceutical compositions thereof
JP2010514725A5 (enExample)
PH12017501690A1 (en) Crystal of 3,5-disubstituted benzene alkynyl compound
CN102471342A (zh) 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
TW201536774A (zh) 經取代之四氫咔唑及咔唑甲醯胺化合物
JP2007532560A5 (enExample)
HU228423B1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
JP2015522037A5 (enExample)
EP3625234A1 (en) Compounds, compositions and methods
JP2011527687A5 (enExample)
JPWO2021033729A5 (enExample)
JP2016515550A5 (enExample)
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
KR20210039417A (ko) 치환된 테트라하이드로사이클로펜타[c]피롤, 치환된 디하이드로피롤리진, 이의 유사체, 및 이의 사용 방법